Alvotech (ALVO)

Mar 28, 2025, 5:01 PM EDT - 6 days ago

This Is a Test From GlobeNewswire

CMPS

Mar 27, 2025, 12:09 PM EDT - 7 days ago

Alvotech (ALVO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:30 AM EDT - 7 days ago

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Mar 26, 2025, 6:36 PM EDT - 8 days ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 6:34 PM EDT - 8 days ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 4:30 AM EDT - 8 days ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 26, 2025, 4:30 AM EDT - 8 days ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 20, 2025, 3:00 AM EDT - 14 days ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 20, 2025, 3:00 AM EDT - 14 days ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 7, 2025, 9:00 AM EST - 27 days ago

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Feb 24, 2025, 8:00 AM EST - 5 weeks ago

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Feb 21, 2025, 6:44 AM EST - 5 weeks ago

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

JNJ TEVA

Feb 21, 2025, 6:00 AM EST - 5 weeks ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Feb 18, 2025, 11:30 AM EST - 6 weeks ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

TEVA

Feb 18, 2025, 6:00 AM EST - 6 weeks ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Jan 27, 2025, 6:00 AM EST - 2 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Dec 23, 2024, 4:00 AM EST - 3 months ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Nov 21, 2024, 2:02 AM EST - 4 months ago

Alvotech's Position In The Coming Biosimilar Gold Rush

Nov 15, 2024, 8:00 AM EST - 4 months ago

Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors

Nov 14, 2024, 1:59 PM EST - 5 months ago

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:00 AM EST - 5 months ago

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024

Nov 4, 2024, 7:00 AM EST - 5 months ago

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Oct 25, 2024, 8:00 AM EDT - 5 months ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Oct 10, 2024, 5:01 AM EDT - 6 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Oct 2, 2024, 12:08 PM EDT - 6 months ago

Alvotech (ALVO) Shares Up 3.77% on Oct 2

Sep 25, 2024, 5:01 AM EDT - 6 months ago

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Aug 26, 2024, 9:15 AM EDT - 7 months ago

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 8:00 AM EDT - 7 months ago

Alvotech: Steady Progress Offers A Good Chance Of Upside

Aug 16, 2024, 10:27 AM EDT - 8 months ago

Alvotech (ALVO) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 4:15 PM EDT - 8 months ago

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

Aug 15, 2024, 4:30 AM EDT - 8 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Aug 1, 2024, 4:02 PM EDT - 8 months ago

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

Jul 22, 2024, 6:35 AM EDT - 9 months ago

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

Jul 11, 2024, 4:45 AM EDT - 9 months ago

Alvotech Announces Closing of Private Debt Financing

Jul 1, 2024, 5:35 PM EDT - 9 months ago

Alvotech Issues New Shares to Holders of Convertible Bonds

Jul 1, 2024, 5:10 AM EDT - 9 months ago

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

Jun 26, 2024, 4:50 AM EDT - 10 months ago

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

Jun 18, 2024, 4:01 AM EDT - 10 months ago

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Jun 11, 2024, 4:00 AM EDT - 10 months ago

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

Jun 11, 2024, 4:00 AM EDT - 10 months ago

Alvotech and STADA add to strategic alliance through denosumab partnership

Jun 7, 2024, 4:00 AM EDT - 10 months ago

Alvotech Announces Strategic Refinancing Agreement

May 29, 2024, 8:05 AM EDT - 11 months ago

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

May 22, 2024, 12:55 PM EDT - 11 months ago

Alvotech (ALVO) Q1 2024 Earnings Call Transcript

May 21, 2024, 5:15 PM EDT - 11 months ago

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

May 21, 2024, 8:01 AM EDT - 11 months ago

Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 20, 2024, 8:25 PM EDT - 11 months ago

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 20, 2024, 8:25 PM EDT - 11 months ago

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 15, 2024, 9:30 AM EDT - 11 months ago

Alvotech S.A. Annual General Meeting to be held June 7, 2024

May 13, 2024, 8:00 AM EDT - 11 months ago

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

May 2, 2024, 7:15 AM EDT - 1 year ago

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024